Payment overview · 2025
General Payments
$81.26
3 reported records · 3 companies
Healthcare provider profile · identity verified
Mark Albert Bigda, DO
Allopathic & Osteopathic Physicians|Internal Medicine · EASTHAMPTON, MA · NPI 1043292089
Verified facts
What the public records show
CMS Open Payments records show Mark Albert Bigda, DO received $81.26 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.03 | 38.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.75 | 32.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.48 | 28.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.26 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 294 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 66 |
| Omeprazole | Omeprazole | 190 | 62 |
| Tramadol Hcl | Tramadol Hcl | 189 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 45 |
| Losartan Potassium | Losartan Potassium | 154 | 38 |
| Eliquis | Apixaban | 130 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 38 |
| Trazodone Hcl | Trazodone Hcl | 125 | 33 |
| Simvastatin | Simvastatin | 120 | 32 |
| Lorazepam | Lorazepam | 116 | 32 |
| Mirtazapine | Mirtazapine | 111 | 23 |
| Furosemide | Furosemide | 108 | 37 |
| Meloxicam | Meloxicam | 98 | 27 |
| Trulicity | Dulaglutide | 98 | 17 |
| Allopurinol | Allopurinol | 97 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 22 |
| Jardiance | Empagliflozin | 94 | 16 |
| Alprazolam | Alprazolam | 91 | 20 |
| Prednisone | Prednisone | 89 | 31 |
| Atenolol | Atenolol | 88 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 19 |
| Glimepiride | Glimepiride | 80 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 23 |
| Gabapentin | Gabapentin | 75 | 14 |
| Metformin Hcl | Metformin Hcl | 72 | 21 |
| Carvedilol | Carvedilol | 70 | 13 |
| Azithromycin | Azithromycin | 65 | 57 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Ozempic | Semaglutide | 63 | 11 |
| Lovastatin | Lovastatin | 60 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 57 | 15 |
| Pregabalin | Pregabalin | 55 | 13 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Spironolactone | Spironolactone | 51 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 14 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 11 |
| Methylprednisolone | Methylprednisolone | 41 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 13 |
| Donepezil Hcl | Donepezil Hcl | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 12 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Testosterone | Testosterone | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Nystatin | Nystatin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.26 · 3 records | Abbott Laboratories | FREESTYLE LIBRE 3, MOUNJARO, REXULTI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error